PLYX (Polaryx Therapeutics) Ending Cash Position: $3.08 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.31
View Full Analysis

What is Polaryx Therapeutics Ending Cash Position?

Polaryx Therapeutics PLYX -4.15% 13 Ending Cash Position is $3.08 Mil as of Mar. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100.

Polaryx Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $3.08 Mil.

Polaryx Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($5.75 Mil) to Dec. 2025 ($5.14 Mil) and declined from Dec. 2025 ($5.14 Mil) to Mar. 2026 ($3.08 Mil).

Polaryx Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($4.62 Mil) and increased from Dec. 2024 ($4.62 Mil) to Dec. 2025 ($5.14 Mil).

Polaryx Therapeutics Ending Cash Position Related Terms

Polaryx Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics Ending Cash Position Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
0.00 4.62 5.14

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.16 3.30 5.75 5.14 3.08
PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Polaryx Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.621+0.522
=5.14

Polaryx Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.143+-2.063
=3.08

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $3.08 Mil mean?
Polaryx Therapeutics (PLYX) has a Ending Cash Position of $3.08 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' Ending Cash Position too high?
Polaryx Therapeutics' current Ending Cash Position is $3.08 Mil. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Ending Cash Position compare to GUTS and NTHI?
Polaryx Therapeutics' Ending Cash Position of $3.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Ending Cash Position is $3.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current Ending Cash Position of $3.08 Mil. The current Ending Cash Position is $3.08 Mil. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current Ending Cash Position is $3.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price